单域抗体在肿瘤分子影像学中的研究进展
|
摘要
单域抗体(single-domain antibody, sdAb)是一种从骆驼科动物血清中提取的仅具有重链的抗体的可变区。单域抗体具有易表达、水溶性好、稳定性强、免疫原性弱等特点。与常规抗体相比,单域抗体在组织中的穿透率更高,并且能够通过肾脏被快速清除,使其能被理想地应用于各种生物技术和肿瘤临床治疗。单价sdAbs可以与放射性同位素、荧光染料、生物素、磁珠、亲和基质等化学物质偶联形成复合型分子偶联的sdAbs,可用于多种模式的在体肿瘤成像,在基础研究、探针开发等领域有着广阔的应用前景。本文就单域抗体的分子特征和其在肿瘤分子影像学中的应用进行综述。
A single-domain antibody(sdAb) is the variable region extracted from antibodies with only heavy chains found in camelid serum. Single-domain antibodies have the characteristics of easy expression, good solubility, great stability and weak immunogenicity. Since single-domain antibodies have higher penetration in tissues than conventional antibodies and can be cleared by the kidneys quickly, they are ideally suited for various biotechnologies and clinical treatment of tumors. The monovalent sdAb could be coupled to radioisotopes, fluorescent dyes, biotin, magnetic beads, affinity matrices and so on. A complex molecularconjugated sdAb can be used for in vivo multiple modes tumor imaging. In the basic research, development of probe and other fields, single-domain antibody has a broad prospect in application. This review summarizes the molecular features and the applications in tumor molecular imaging of single-domain antibodies.
A single-domain antibody(sdAb) is the variable region extracted from antibodies with only heavy chains found in camelid serum. Single-domain antibodies have the characteristics of easy expression, good solubility, great stability and weak immunogenicity. Since single-domain antibodies have higher penetration in tissues than conventional antibodies and can be cleared by the kidneys quickly, they are ideally suited for various biotechnologies and clinical treatment of tumors. The monovalent sdAb could be coupled to radioisotopes, fluorescent dyes, biotin, magnetic beads, affinity matrices and so on. A complex molecularconjugated sdAb can be used for in vivo multiple modes tumor imaging. In the basic research, development of probe and other fields, single-domain antibody has a broad prospect in application. This review summarizes the molecular features and the applications in tumor molecular imaging of single-domain antibodies.
引文
[1]Hamers-Casterman C,Atarhouch T,Muyldermans S,et al.Naturally occurring antibodies devoid of light chains[J].Nature,1993,363(6428):446-8.
[2]Greenberg AS,Avila D,Hughes M,et al.A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks[J].Nature,1995,374(6518):168-73.
[3]Gonzalez-Sapienza G,Rossotti MA,Tabares-da Rosa S.SingleDomain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications[J].Front Immunol,2017,8:977.
[4]Muyldermans S,Smider VV.Distinct antibody species:structural differences creating therapeutic opportunities[J].Curr Opin Immunol,2016,40:7-13.
[5]Arbabi-Ghahroudi M.Camelid Single-Domain Antibodies:Historical Perspective and Future Outlook[J].Front Immunol,2017,8:1589.
[6]Schusser B,Collarini EJ,Pedersen D,et al.Expression of heavy chain-only antibodies can support B-cell development in light chain knockout chickens[J].Eur J Immunol,2016,46(9):2137-48.
[7]Kazemi-Lomedasht F,Muyldermans S,Habibi-Anbouhi M,et al.Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function[J].Iran J Basic Med Sci,2018,21(3):260-6.
[8]Liu JL,Shriver-Lake LC,Anderson GP,et al.Selection,characterization,and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein[J].Microb Cell Fact,2017,16(1):223.
[9]Ti a n B,Wo n g W Y,U g e r M D,e t a l.D e v e l o p m e n t a n d Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2[J].Front Immunol,2017,8:956.
[10]Smolarek D,Bertrand O,Czerwinski M.Variable fragments of heavy chain antibodies(VHHs):a new magic bullet molecule of medicine?[J].Post?py Hig Med Do?w(Online),2012,66:348-58.
[11]Fernandes CFC,Pereira SDS,Luiz MB,et al.Camelid singledomain antibodies as an alternative to overcome challenges related to the prevention,detection,and control of neglected tropical diseases[J].Front Immunol,2017,8:653.
[12]Ladenson RC,Crimmins DL,Landt Y,et al.Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment[J].Anal Chem,2006,78(13):4501-8.
[13]Kleiná,Kovács M,Muskotál A,et al.Nanobody-Displaying Flagellar Nanotubes[J].Sci Rep,2018,8(1):3584.
[14]Goldman ER,Broussard A,Anderson GP,et al.Bglbrick strategy for the construction of single domain antibody fusions[J].Heliyon,2017,3(12):e00474.
[15]Huang L,Gainkam LO,Caveliers V,et al.SPECT imaging with99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression[J].Mol Imaging Biol,2008,10(3):167-75.
[16]Krüwel T,Nevoltris D,Bode J,et al.In vivo detection of small tumour lesions by multi-pinhole SPECT applying a 99mTc-labelled nanobody targeting the Epidermal Growth Factor Receptor[J].Sci Rep,2016,6:21834.
[17]Menke-van der Houven van Oordt CW,Gootjes EC,Huisman MC,et al.89Zr-cetuximab PET imaging in patients with advanced colorectal cancer[J].Oncotarget,2015,6(30):30384-93.
[18]Keyaerts M,Xavier C,Heemskerk J,et al.Phase I study of 68GaHER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma[J].J Nucl Med,2016,57(1):27-33.
[19]Kruziki MA,Case BA,Chan JY,et al.64Cu-labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor[J].Mol Pharm,2016,13(11):3747-55.
[20]Vaneycken I,Govaert J,Vincke C,et al.In vitro analysis and in vivo tumor targeting of a humanized,grafted nanobody in mice using pinhole SPECT/micro-CT[J].J Nucl Med,2010,51(7):1099-106.
[21]Chakravarty R,Goel S,Cai W.Nanobody:The“magic bullet”for molecular imaging?[J].Theranostics,2014,4(4):386-98.
[22]van Brussel AS,Adams A,Oliveira S,et al.Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of PreInvasive Breast Cancer[J].Mol Imaging Biol,2016,18(4):535-44.
[23]Oliveira S,van Dongen GA,Stigter-van Waisum M,et al.Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody[J].Mol Imaging,2012,11(1):33-46.
[24]Hernot S,Unnikrishnan S,Du Z,et al.Nanobody-coupled microbubbles as novel molecular tracer[J].J Control Release,2012,158(2):346-53.
[25]Hu Y,Liu C,Muyldermans S.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy[J].Front Immunol,2017,8:1442.
[26]Bedford R,Tiede C,Hughes R,et al.Alternative reagents to antibodies in imaging applications[J].Biophys Rev,2017,9(4):299-308.
[27]Ding H,Gangalum PR,Galstyan A,et al.HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug[J].Nanomedicine,2017,13(2):631-9.
[28]Iezzi ME,Policastro L,Werbajh S,et al.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment[J].Front Immunol,2018,9:273.
[29]Zheng F,Perlman H,Matthys P,et al.Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies[J].Sci Rep,2016,6:35966.
[2]Greenberg AS,Avila D,Hughes M,et al.A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks[J].Nature,1995,374(6518):168-73.
[3]Gonzalez-Sapienza G,Rossotti MA,Tabares-da Rosa S.SingleDomain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications[J].Front Immunol,2017,8:977.
[4]Muyldermans S,Smider VV.Distinct antibody species:structural differences creating therapeutic opportunities[J].Curr Opin Immunol,2016,40:7-13.
[5]Arbabi-Ghahroudi M.Camelid Single-Domain Antibodies:Historical Perspective and Future Outlook[J].Front Immunol,2017,8:1589.
[6]Schusser B,Collarini EJ,Pedersen D,et al.Expression of heavy chain-only antibodies can support B-cell development in light chain knockout chickens[J].Eur J Immunol,2016,46(9):2137-48.
[7]Kazemi-Lomedasht F,Muyldermans S,Habibi-Anbouhi M,et al.Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function[J].Iran J Basic Med Sci,2018,21(3):260-6.
[8]Liu JL,Shriver-Lake LC,Anderson GP,et al.Selection,characterization,and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein[J].Microb Cell Fact,2017,16(1):223.
[9]Ti a n B,Wo n g W Y,U g e r M D,e t a l.D e v e l o p m e n t a n d Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2[J].Front Immunol,2017,8:956.
[10]Smolarek D,Bertrand O,Czerwinski M.Variable fragments of heavy chain antibodies(VHHs):a new magic bullet molecule of medicine?[J].Post?py Hig Med Do?w(Online),2012,66:348-58.
[11]Fernandes CFC,Pereira SDS,Luiz MB,et al.Camelid singledomain antibodies as an alternative to overcome challenges related to the prevention,detection,and control of neglected tropical diseases[J].Front Immunol,2017,8:653.
[12]Ladenson RC,Crimmins DL,Landt Y,et al.Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment[J].Anal Chem,2006,78(13):4501-8.
[13]Kleiná,Kovács M,Muskotál A,et al.Nanobody-Displaying Flagellar Nanotubes[J].Sci Rep,2018,8(1):3584.
[14]Goldman ER,Broussard A,Anderson GP,et al.Bglbrick strategy for the construction of single domain antibody fusions[J].Heliyon,2017,3(12):e00474.
[15]Huang L,Gainkam LO,Caveliers V,et al.SPECT imaging with99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression[J].Mol Imaging Biol,2008,10(3):167-75.
[16]Krüwel T,Nevoltris D,Bode J,et al.In vivo detection of small tumour lesions by multi-pinhole SPECT applying a 99mTc-labelled nanobody targeting the Epidermal Growth Factor Receptor[J].Sci Rep,2016,6:21834.
[17]Menke-van der Houven van Oordt CW,Gootjes EC,Huisman MC,et al.89Zr-cetuximab PET imaging in patients with advanced colorectal cancer[J].Oncotarget,2015,6(30):30384-93.
[18]Keyaerts M,Xavier C,Heemskerk J,et al.Phase I study of 68GaHER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma[J].J Nucl Med,2016,57(1):27-33.
[19]Kruziki MA,Case BA,Chan JY,et al.64Cu-labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor[J].Mol Pharm,2016,13(11):3747-55.
[20]Vaneycken I,Govaert J,Vincke C,et al.In vitro analysis and in vivo tumor targeting of a humanized,grafted nanobody in mice using pinhole SPECT/micro-CT[J].J Nucl Med,2010,51(7):1099-106.
[21]Chakravarty R,Goel S,Cai W.Nanobody:The“magic bullet”for molecular imaging?[J].Theranostics,2014,4(4):386-98.
[22]van Brussel AS,Adams A,Oliveira S,et al.Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of PreInvasive Breast Cancer[J].Mol Imaging Biol,2016,18(4):535-44.
[23]Oliveira S,van Dongen GA,Stigter-van Waisum M,et al.Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody[J].Mol Imaging,2012,11(1):33-46.
[24]Hernot S,Unnikrishnan S,Du Z,et al.Nanobody-coupled microbubbles as novel molecular tracer[J].J Control Release,2012,158(2):346-53.
[25]Hu Y,Liu C,Muyldermans S.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy[J].Front Immunol,2017,8:1442.
[26]Bedford R,Tiede C,Hughes R,et al.Alternative reagents to antibodies in imaging applications[J].Biophys Rev,2017,9(4):299-308.
[27]Ding H,Gangalum PR,Galstyan A,et al.HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug[J].Nanomedicine,2017,13(2):631-9.
[28]Iezzi ME,Policastro L,Werbajh S,et al.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment[J].Front Immunol,2018,9:273.
[29]Zheng F,Perlman H,Matthys P,et al.Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies[J].Sci Rep,2016,6:35966.